SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dishman Carbogen Amc - Quaterly Results

23 May 2023 Evaluate
The sales moved up 34.12% to Rs. 1131.30 millions for the March 2023 quarter as compared to Rs. 843.50 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -102.30 millions as compared to Net Profit of Rs. 48.30 millions of corresponding quarter ended March 2022The company reported a good operating profit of 211.40 millions compared to 145.20 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 1131.30 843.50 34.12 4025.50 3066.10 31.29 4025.50 3066.10 31.29
Other Income 147.90 114.30 29.40 521.60 603.90 -13.63 521.60 603.90 -13.63
PBIDT 211.40 145.20 45.59 599.20 999.00 -40.02 599.20 999.00 -40.02
Interest 170.30 100.30 69.79 579.20 372.30 55.57 579.20 372.30 55.57
PBDT 41.10 10.80 280.56 0.00 567.60 -100.00 0.00 567.60 -100.00
Depreciation 234.50 344.90 -32.01 962.00 1400.70 -31.32 962.00 1400.70 -31.32
PBT -193.40 -334.10 -42.11 -962.00 -833.10 15.47 -962.00 -833.10 15.47
TAX -91.10 -382.40 -76.18 -373.30 -528.40 -29.35 -373.30 -528.40 -29.35
Deferred Tax -91.10 -75.60 20.50 -373.30 -221.60 68.46 -373.30 -221.60 68.46
PAT -102.30 48.30 -311.80 -588.70 -304.70 93.21 -588.70 -304.70 93.21
Equity 313.60 313.60 0.00 313.60 313.60 0.00 313.60 313.60 0.00
PBIDTM(%) 18.69 17.21 8.55 14.89 32.58 -54.32 14.89 32.58 -54.32

Dishman Carbogen Amc Share Price

167.55 -1.05 (-0.62%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×